Literature DB >> 15540893

Bcl-2-related genes in lymphoid neoplasia.

Michael C Wei1.   

Abstract

The proto-oncogene BCL-2 was discovered with the cloning of the t(14;18) chromosomal translocation responsible for human follicular lymphoma. Since then other members of the Bcl-2 family of cell death regulators have been identified and their roles in cell death, normal lymphoid development, and lymphoid neoplasia have been characterized. Bcl-2 family members are important in tumor initiation, progression, and response to chemotherapy, and altered expression levels of various members serve as prognostic markers in many lymphoid malignancies. There are promising cancer therapeutics now targeted at members of the Bcl-2 family.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15540893     DOI： 10.1532/ijh97.04110

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  57 in total

1.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis.

Authors:  E Oda; R Ohki; H Murasawa; J Nemoto; T Shibue; T Yamashita; T Tokino; T Taniguchi; N Tanaka
Journal:  Science       Date:  2000-05-12       Impact factor: 47.728

2.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.

Authors:  Anthony Letai; Michael C Bassik; Loren D Walensky; Mia D Sorcinelli; Solly Weiler; Stanley J Korsmeyer
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

3.  BCL-XL-regulated apoptosis in T cell development.

Authors:  D T Chao; S J Korsmeyer
Journal:  Int Immunol       Date:  1997-09       Impact factor: 4.823

4.  Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study.

Authors:  F M Uckun; Z Yang; H Sather; P Steinherz; J Nachman; B Bostrom; L Crotty; M Sarquis; O Ek; T Zeren; D Tubergen; G Reaman; P Gaynon
Journal:  Blood       Date:  1997-05-15       Impact factor: 22.113

5.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis.

Authors:  E H Cheng; M C Wei; S Weiler; R A Flavell; T W Mak; T Lindsten; S J Korsmeyer
Journal:  Mol Cell       Date:  2001-09       Impact factor: 17.970

6.  Proapoptotic BID is required for myeloid homeostasis and tumor suppression.

Authors:  Sandra S Zinkel; Christy C Ong; David O Ferguson; Hiromi Iwasaki; Koichi Akashi; Roderick T Bronson; Jeffery L Kutok; Frederick W Alt; Stanley J Korsmeyer
Journal:  Genes Dev       Date:  2003-01-15       Impact factor: 11.361

7.  Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.

Authors:  Joseph T Opferman; Anthony Letai; Caroline Beard; Mia D Sorcinelli; Christy C Ong; Stanley J Korsmeyer
Journal:  Nature       Date:  2003-12-11       Impact factor: 49.962

8.  The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues.

Authors:  T Lindsten; A J Ross; A King; W X Zong; J C Rathmell; H A Shiels; E Ulrich; K G Waymire; P Mahar; K Frauwirth; Y Chen; M Wei; V M Eng; D M Adelman; M C Simon; A Ma; J A Golden; G Evan; S J Korsmeyer; G R MacGregor; C B Thompson
Journal:  Mol Cell       Date:  2000-12       Impact factor: 17.970

9.  Bax-deficient mice with lymphoid hyperplasia and male germ cell death.

Authors:  C M Knudson; K S Tung; W G Tourtellotte; G A Brown; S J Korsmeyer
Journal:  Science       Date:  1995-10-06       Impact factor: 47.728

10.  BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis.

Authors:  Luca Scorrano; Scott A Oakes; Joseph T Opferman; Emily H Cheng; Mia D Sorcinelli; Tullio Pozzan; Stanley J Korsmeyer
Journal:  Science       Date:  2003-03-06       Impact factor: 47.728
View more
  8 in total

1.  Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo.

Authors:  S Ackler; M J Mitten; J Chen; J Clarin; K Foster; S Jin; D C Phillips; S Schlessinger; B Wang; J D Leverson; E R Boghaert
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

2.  Lupeol enhances inhibitory effect of 5-fluorouracil on human gastric carcinoma cells.

Authors:  Yan Liu; Tingting Bi; Wei Dai; Gang Wang; Liqiang Qian; Genhai Shen; Quangen Gao
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-02-19       Impact factor: 3.000

3.  Synergistic effect of oxymatrine and angiogenesis inhibitor NM-3 on modulating apoptosis in human gastric cancer cells.

Authors:  Ming-Quan Song; Jin-Shui Zhu; Jin-Lian Chen; Long Wang; Wei Da; Li Zhu; Wei-Ping Zhang
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

4.  Induction of apoptosis promoted by Bang52; a small molecule that downregulates Bcl-x(L).

Authors:  Matteo Rossi; Jeong-Kyu Bang; Sharlyn Mazur; Jaclyn A Iera; Darren C Phillips; Gerard P Zambetti; Daniel H Appella
Journal:  Bioorg Med Chem Lett       Date:  2009-03-21       Impact factor: 2.823

5.  Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias.

Authors:  Deborah L Hodge; Jun Yang; Matthew D Buschman; Paul M Schaughency; Hong Dang; William Bere; Yili Yang; Ram Savan; Jeff J Subleski; Xiao-Ming Yin; Thomas P Loughran; Howard A Young
Journal:  Cancer Res       Date:  2009-04-14       Impact factor: 12.701

6.  Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax.

Authors:  Scott Ackler; Anatol Oleksijew; Jun Chen; Brenda J Chyla; Jerry Clarin; Kelly Foster; Thomas McGonigal; Sasmita Mishra; Sally Schlessinger; Morey L Smith; Stephen K Tahir; Joel D Leverson; Andrew J Souers; Erwin R Boghaert; Jonathan Hickson
Journal:  Pharmacol Res Perspect       Date:  2015-09-01

7.  Polyphenols from Broussonetia papyrifera Induce Apoptosis of HepG2 Cells via Inactivation of ERK and AKT Signaling Pathways.

Authors:  Chen-Zhuo Dou; Yan-Fen Liu; Lu-Lu Zhang; Shao-Hong Chen; Chuan-Yin Hu; You Liu; Yun-Tao Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2021-03-23       Impact factor: 2.629

Review 8.  A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.

Authors:  Faroogh Marofi; Heshu Sulaiman Rahman; Muhammad Harun Achmad; Klunko Nataliya Sergeevna; Wanich Suksatan; Walid Kamal Abdelbasset; Maria Vladimirovna Mikhailova; Navid Shomali; Mahboubeh Yazdanifar; Ali Hassanzadeh; Majid Ahmadi; Roza Motavalli; Yashwant Pathak; Sepideh Izadi; Mostafa Jarahian
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.